FDA Delays Full Approval of Novavax COVID-19 Vaccine, Requests More Data

The U.S. Food and Drug Administration (FDA) has asked Novavax to commit to providing additional clinical data on its COVID-19 vaccine before granting full approval. This request follows the agency’s missed April 1 deadline to make a decision on traditional approval for the shot.

What’s the Issue?

Although Novavax’s vaccine has been available under emergency use authorization since 2022, it hasn’t yet received full FDA approval. Now, the agency wants more post-marketing studies — research conducted after the vaccine hits the market — to ensure its long-term safety and effectiveness.

Novavax, in response, says it still believes the vaccine is “approvable” and is working quickly to address the FDA’s requirements.

Why It Matters

Unlike Pfizer and Moderna’s mRNA-based COVID-19 vaccines, Novavax uses a protein-based approach, offering an alternative for those who prefer non-mRNA options. However, it has faced stiff competition in the U.S. market and slower rollout due to regulatory hurdles.

Behind the Delay

The delay in approval may also be linked to leadership changes within the FDA, including a new acting director at the Center for Biologics Evaluation and Research. These internal shifts may have contributed to the missed decision deadline.

What’s Next?

If Novavax complies with the FDA’s request, full approval may still be on the horizon, but not without more data and time. For now, the vaccine remains available under emergency use, especially for those seeking options beyond mRNA technology.